
After FDA nod, Pfizer joins GSK in RSV vaccine market
The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in th
Newsletters and Deep Dive digital magazine
The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in th
On Tuesday afternoon, 23rd May, pharmaphorum headed over to The Royal Society of Medicine to learn more about how the pharmaceutical industry goes about securing market access to medicines
The pharmaceutical industry has arguably been slow to prioritise the environment and sustainable strategies.
Pfizer’s Vydura has become the first oral CGRP antagonist recommended for routine use by the NHS to prevent episodic migraine attacks, after being rejected earlier this ye
Iovance Biotherapeutics could be a few months away from a first regulatory approval for lifileucel, which could be the first cell-based therapy for a solid tumour in the U
Editor's Picks
Newsletters and Deep Dive
digital magazine